What does Pharmstandard invest in?
Pharmstandard invests most often at Series B and Series D (86% of the rounds on record), in sectors such as Biotechnology, Manufacturing and Pharmaceutical.
Last cheque observed Dec 2017. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.
QuietCorporate VC
8 rounds on record
Mostly Series B and Series D: 86% of its rounds
Sole investor in 1 rounds, median $4.0M
Every round we can evidence, newest first8 appearances
2 rounds
2 rounds
2 rounds
2 rounds
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
From their own portfolio page (on their website)
Disclosure of informationPh2014
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
The investors most often in the same rounds as Pharmstandard. A count of rooms they were both in, not a relationship either has claimed.
Pharmstandard invests most often at Series B and Series D (86% of the rounds on record), in sectors such as Biotechnology, Manufacturing and Pharmaceutical.
8 investments on record, 0 of them in the last 12 months. The most recent was in Dec 2017.
Its most recent investments on record: OncoTartis (Undisclosed round, Dec 2017) and Neon Therapeutics (Series B, Dec 2017).
The median round it joins is $21M.
Rarely, if at all: none of its 8 investments on record names it as the lead.
Most of the companies it backs are in the United States (75%), Canada (13%) and Australia (13%).
No investments in the last 12 months; the latest was in Dec 2017.
Most often Bessemer Venture Partners (2 rounds together), Casdin Capital (2 rounds together) and Intersouth Partners (2 rounds together).
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it